MX2019009986A - Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias. - Google Patents
Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias.Info
- Publication number
- MX2019009986A MX2019009986A MX2019009986A MX2019009986A MX2019009986A MX 2019009986 A MX2019009986 A MX 2019009986A MX 2019009986 A MX2019009986 A MX 2019009986A MX 2019009986 A MX2019009986 A MX 2019009986A MX 2019009986 A MX2019009986 A MX 2019009986A
- Authority
- MX
- Mexico
- Prior art keywords
- neurodegenerative
- cell activation
- early detection
- glial cell
- neuroinflammatory diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461945P | 2017-02-22 | 2017-02-22 | |
| PCT/US2018/018794 WO2018156509A1 (en) | 2017-02-22 | 2018-02-20 | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009986A true MX2019009986A (es) | 2019-10-14 |
Family
ID=63253999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009986A MX2019009986A (es) | 2017-02-22 | 2018-02-20 | Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190383836A1 (enExample) |
| EP (1) | EP3585435A4 (enExample) |
| JP (1) | JP7626416B2 (enExample) |
| KR (1) | KR102533921B1 (enExample) |
| CN (1) | CN110325213A (enExample) |
| AU (1) | AU2018225493B2 (enExample) |
| BR (1) | BR112019017367A2 (enExample) |
| CA (1) | CA3050328A1 (enExample) |
| IL (1) | IL267940B2 (enExample) |
| MX (1) | MX2019009986A (enExample) |
| RU (1) | RU2766341C2 (enExample) |
| SG (1) | SG11201906670PA (enExample) |
| WO (1) | WO2018156509A1 (enExample) |
| ZA (1) | ZA201904431B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2427212T3 (enExample) | 2009-05-08 | 2018-01-20 | ||
| CN104168956A (zh) | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| BR112015032690B1 (pt) | 2013-06-25 | 2020-03-10 | Vaccinex, Inc. | Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase |
| NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| BR112018071686A2 (pt) | 2016-04-22 | 2019-02-19 | Vaccinex, Inc. | exibição de proteínas integrais de membrana em vírions extracelulares envelopados de poxvírus |
| WO2018026715A1 (en) | 2016-08-02 | 2018-02-08 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| CN117597360A (zh) * | 2020-06-25 | 2024-02-23 | 瓦西尼斯公司 | 脑信号蛋白-4d结合分子在rett综合征治疗中的应用 |
| CA3231551A1 (en) * | 2021-09-27 | 2023-03-30 | Maurice Zauderer | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
| AU2024243083A1 (en) * | 2023-04-03 | 2025-11-20 | Sialbio Co., Ltd. | Pharmaceutical composition for preventing or treating sjogren's syndrome, containing recombinant anti-semaphorin 4d antibody as active ingredient |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
| KR101603917B1 (ko) * | 2008-05-09 | 2016-03-17 | 애브비 인코포레이티드 | 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도 |
| CN104168956A (zh) * | 2011-10-11 | 2014-11-26 | 瓦西尼斯公司 | 臂板蛋白-4d结合分子用于调节血脑屏障渗透性的用途 |
| US10494440B2 (en) * | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
| NZ630881A (en) * | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
| NZ630892A (en) * | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
| WO2017011746A1 (en) * | 2015-07-15 | 2017-01-19 | Adm Diagnostics, Llc | System and methods for determining a brain condition of a patient sybject to multiple disease states |
-
2018
- 2018-02-20 WO PCT/US2018/018794 patent/WO2018156509A1/en not_active Ceased
- 2018-02-20 EP EP18757318.3A patent/EP3585435A4/en active Pending
- 2018-02-20 RU RU2019122337A patent/RU2766341C2/ru active
- 2018-02-20 MX MX2019009986A patent/MX2019009986A/es unknown
- 2018-02-20 CN CN201880013208.3A patent/CN110325213A/zh active Pending
- 2018-02-20 KR KR1020197027287A patent/KR102533921B1/ko active Active
- 2018-02-20 US US16/488,123 patent/US20190383836A1/en not_active Abandoned
- 2018-02-20 BR BR112019017367A patent/BR112019017367A2/pt unknown
- 2018-02-20 SG SG11201906670PA patent/SG11201906670PA/en unknown
- 2018-02-20 IL IL267940A patent/IL267940B2/en unknown
- 2018-02-20 JP JP2019566047A patent/JP7626416B2/ja active Active
- 2018-02-20 AU AU2018225493A patent/AU2018225493B2/en active Active
- 2018-02-20 CA CA3050328A patent/CA3050328A1/en active Pending
-
2019
- 2019-07-05 ZA ZA2019/04431A patent/ZA201904431B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018156509A1 (en) | 2018-08-30 |
| EP3585435A1 (en) | 2020-01-01 |
| JP2020510845A (ja) | 2020-04-09 |
| AU2018225493A1 (en) | 2019-08-01 |
| NZ755446A (en) | 2025-06-27 |
| ZA201904431B (en) | 2024-11-27 |
| EP3585435A4 (en) | 2020-12-16 |
| CN110325213A (zh) | 2019-10-11 |
| RU2019122337A3 (enExample) | 2021-06-09 |
| JP7626416B2 (ja) | 2025-02-04 |
| IL267940A (en) | 2019-09-26 |
| IL267940B2 (en) | 2025-04-01 |
| RU2019122337A (ru) | 2021-03-23 |
| RU2766341C2 (ru) | 2022-03-15 |
| IL267940B1 (en) | 2024-12-01 |
| SG11201906670PA (en) | 2019-08-27 |
| KR20190120784A (ko) | 2019-10-24 |
| BR112019017367A2 (pt) | 2020-04-14 |
| CA3050328A1 (en) | 2018-08-30 |
| AU2018225493B2 (en) | 2025-03-06 |
| US20190383836A1 (en) | 2019-12-19 |
| KR102533921B1 (ko) | 2023-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019009986A (es) | Deteccion temprana de la activacion de celulas gliales en enfermedades neurodegenerativas o neuroinflamatorias. | |
| CY1122245T1 (el) | Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου | |
| MX2022010225A (es) | Compuestos que interactuan con la superfamilia ras para el tratamiento de canceres, enfermedades inflamatorias, rasopatias y enfermedad fibrotica. | |
| MX2019003474A (es) | Metodos mejorados para evaluar el estado de la proteina acidica fibrilar glial (gfap) en muestras de pacientes. | |
| EP3405896A4 (en) | SYSTEMS AND METHOD FOR IMPROVED DIAGNOSIS OF ILLNESSES | |
| CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
| BR112013010952A2 (pt) | sistemas de rmn e métodos para a detecção rápida de analisados | |
| MA42238A (fr) | Procédés de diagnostic du cancer de la vessie | |
| LT3954288T (lt) | Medicinos prietaisas, skirtas bent vienai analizuojamai medžiagai kūno skystyje aptikti | |
| MX2018001697A (es) | Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. | |
| MX2016003103A (es) | Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para tratar tumores. | |
| BR112015022019A2 (pt) | Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer | |
| FR3023617B1 (fr) | Dispositif non invasif de determination de la fertilite et/ou du sexe d’un oeuf, et procede correspondant. | |
| CN106456764A8 (zh) | 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂 | |
| MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
| EA201790504A1 (ru) | Монослой мононуклеарных клеток периферической крови или клеток костного мозга и его применение | |
| MX387627B (es) | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| HK1232238A1 (zh) | 检测人类骨膜蛋白的新型测定 | |
| MX385216B (es) | Prueba de diagnostico basada en fragmento de rgma. | |
| WO2014042828A3 (en) | Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia | |
| WO2016133449A9 (en) | Detection and treatment of malignant tumours in the cns | |
| IL272484A (en) | Systems and methods for improving disease diagnosis using measured test substances | |
| UY37082A (es) | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv | |
| EP3374026A4 (en) | THROMBOZYTE BIOMARKERS AND DIAGNOSTIC METHODS FOR VASCULAR DISEASES |